Bristol Myers Squibb Company $BMY Shares Sold by First Bank & Trust

First Bank & Trust trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 76.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,719 shares of the biopharmaceutical company’s stock after selling 21,612 shares during the quarter. First Bank & Trust’s holdings in Bristol Myers Squibb were worth $303,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Trifecta Capital Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter valued at $25,000. CBIZ Investment Advisory Services LLC boosted its position in shares of Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 231 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in shares of Bristol Myers Squibb in the 1st quarter valued at about $36,000. Finally, REAP Financial Group LLC lifted its stake in shares of Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 428 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on BMY shares. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Wells Fargo & Company raised their price objective on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Scotiabank reaffirmed a “sector perform” rating and set a $53.00 price objective (up from $45.00) on shares of Bristol Myers Squibb in a report on Thursday, December 4th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $54.62.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers publicly announced an agreement with the U.S. government to improve affordability and access to medicines — a company release that frames the deal as preserving market access while responding to pricing pressures. This reduces regulatory uncertainty and the risk of punitive measures that could have hurt sales. Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
• Positive Sentiment: BMY and partner BioNTech reported progress in immunotherapy clinical programs (first-line liver cancer and a kidney‑cancer trial update), which add long-term commercial optionality if late‑stage data confirms benefit. These pipeline moves support upside beyond near‑term pricing headwinds. New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech
• Positive Sentiment: Analyst and media endorsements are visible: Guggenheim raised/maintained an elevated price target after an FDA priority review and media commentators (including Jim Cramer) are calling BMY a buy/value name — these signals can attract momentum and retail/institutional buyers. Guggenheim sets $62 target on Bristol-Myers Squibb Company (BMY) after FDA priority review
• Neutral Sentiment: Major press outlets report that nine pharma companies (including BMY) struck voluntary price agreements with the White House to link some U.S. prices to lower foreign prices and to avoid potential tariffs — this offers regulatory clarity but also implies longer‑term pricing pressure. Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
• Neutral Sentiment: Broader coverage (CNBC) confirms multiple large drugmakers are making similar deals with the administration — increases industry momentum toward pricing reforms but spreads the competitive/market impact across peers. Nine of the largest pharma companies ink deals with Trump to lower drug prices
• Neutral Sentiment: BMY set a Q4 2025 earnings release date (Feb. 5, 2026) — a near‑term catalyst investors will watch for sales impact from pricing agreements and pipeline progress. Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
• Negative Sentiment: Analyst model updates from Zacks Research trimmed several near‑term EPS estimates and cut FY2027 estimates modestly, implying some downward revision risk to earnings expectations if pricing concessions or volume shifts persist. (Zacks research notes summarized across recent releases.)
• Positive Sentiment: Market commentary pieces positioning BMY as a long‑term value stock may attract defensive/value investors given the company’s dividend/cash flow profile and pipeline depth. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Bristol Myers Squibb Stock Up 1.5%

BMY opened at $54.15 on Monday. The firm has a market cap of $110.24 billion, a P/E ratio of 18.29, a PEG ratio of 8.29 and a beta of 0.29. The business’s fifty day simple moving average is $47.73 and its 200 day simple moving average is $47.14. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be issued a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.7%. Bristol Myers Squibb’s payout ratio is presently 83.78%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.